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Abstract 
Background: Presbyopia is the age‑related deterioration in the ability to focus on close objects. In order to develop 
a patient‑reported outcome (PRO) instrument to assess near vision functioning, the Near Activity Visual Questionnaire 
(NAVQ) was adapted to incorporate modern technology (e.g. smartphones) and to be appropriate for use in phakic 
presbyopia, leading to the development of the NAVQ‑Presbyopia (NAVQ‑P). Additional single‑item instruments of 
near vision correction independence (NVCI), correction preference (NVCP), and vision satisfaction (NVS) were also 
developed. The study aimed to evaluate the content validity of the NAVQ‑P and additional instruments in individuals 
with phakic presbyopia.
Methods: Participants in the US (n = 15), Germany (n = 10) and France (n = 10) took part in face‑to‑face, qualitative, 
cognitive debriefing interviews. Seven healthcare professionals (HCPs) were also interviewed to assess the clinical 
relevance of the PRO instruments. Interviews started with open‑ended qualitative concept elicitation questioning; 
participants then completed the PRO instruments on an electronic tablet using a “think‑aloud” process and were 
asked about their understanding and relevance of each item, instruction, response scale and recall period. Interviews 
were conducted in two rounds allowing for modifications between rounds.
Results: The participants interpreted the majority of the PRO instruments and recall period correctly and consist‑
ently. They were able to select an appropriate response option without difficulty. Minor modifications were made 
to the PRO instruments based on interview findings. Instruction/item wording was modified to include reference to 
use of a magnifying glass, in addition to glasses and contact lenses. Two items were added to assess difficulty with 
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Introduction
Presbyopia occurs when the physiologically normal age-
related reduction in the eye’s focusing range reaches a 
point, when optimally corrected for distance vision, that 
the clarity of vision at near is insufficient to satisfy an 
individual’s requirements [1, 2]. It is hypothesized to be 
caused by a loss of lens elasticity preventing focal point 
change [3, 4]. While the etiology of this condition is not 
fully elucidated, recent research suggests that an increase 
in lens rigidity is the primary causative mechanism [5, 6]. 
Presbyopia is expected to be experienced in about 80% of 
people aged 40 years or above [1]. Individuals with pres-
byopia have difficulty with near vision function tasks (e.g. 
reading or threading a needle [7, 8]) and experience bur-
den associated with wearing glasses [9]. Consequently, 
presbyopia has a significant impact on individuals’ health 
related quality of life [7, 8, 10–14] and entails substantial 
humanistic and economic burden [15].
Existing clinical assessment tools (such as visual acuity 
assessment through use of a standardised Snellen chart) 
lack adequate assessment of the individual experience of 
presbyopia, highlighting the need for patient-reported 
outcome (PRO) instruments in this specific population. 
A recent literature review found there was a paucity of 
PROs developed for use in phakic presbyopia in line with 
the Food and Drug Administration (FDA) PRO guid-
ance [16]. Phakic presbyopia is presbyopia that occurs for 
an individual who still has a natural lens, as opposed to 
pseudophakic presbyopia where the individual no longer 
has a natural lens (such as following surgery). There are 
a number of treatment considerations when manag-
ing pseudophakic presbyopia in comparison to phakic 
presbyopia such as navigating corneal scars and residual 
corneal irregularities from prior incisions.{Paley  [17]} 
Instruments such as the Near Activity Visual Question-
naire (NAVQ) [18], National Eye Institute Visual Func-
tion Questionnaire (NEI VFQ-25) [19], National Eye 
Institute Refractive Error Quality of Life Instrument-42 
(NEI RQL-42) [20] were among those identified as PRO 
instruments that assess vision outcomes of presbyopia 
or similar conditions. The FDA guidance outlines the 
requirement of evidence of content validity in a given 
context of use for existing, modified, or newly created 
PRO instruments used to support claims in approved 
medical product labelling [16, 21]. The NAVQ was the 
only PRO identified by the literature review as a suitable 
instrument to assess patient-reported near vision func-
tion [16, 18]. The other identified instruments had limita-
tions such as lack of focus on presbyopia and insufficient 
evidence to support the psychometric properties.
The NAVQ was originally developed and validated 
in a population which included individuals with pseu-
dophakic presbyopia [18]. Although the NAVQ was 
developed in line with the FDA guidance, modifications 
were required to ensure the NAVQ was suitable for use 
in clinical trials with a purely phakic population, and that 
the instrument assessed difficulties experienced with 
the use of modern information technology devices due 
to near-vision problems (smartphones, computers, and 
tablet devices which were not as widely used when the 
NAVQ was first developed). To inform modifications to 
the NAVQ, first an update of the literature review and a 
social media listening study was conducted to explore the 
lived experience of presbyopia [16, 22]. This information 
was used to generate a preliminary conceptual model to 
summarize the key symptoms and impacts in presbyopia.
Based on the preliminary conceptual model, the 
NAVQ was adapted for use with individuals with pha-
kic presbyopia and the resulting instrument is called the 
NAVQ-Presbyopia (NAVQ-P). Additional single-item 
instruments for the assessment of near vision correc-
tion independence (NVCI), near vision correction pref-
erence (NVCP) and near vision satisfaction (NVS) were 
also developed, along with two global items to assess 
patient global impression of severity of near vision func-
tion (PGIS-Presbyopia) and patient global impression of 
change in near vision function (PGIC-Presbyopia). All 
instruments were designed for electronic completion 
using a tablet device. Cognitive debriefing (CD) of the 
electronic NAVQ-P, NVCI and additional instruments 
was required to evaluate content validity of the instru-
ments in individuals with phakic presbyopia.
precision tasks (e.g. sewing) and taking longer to adjust from distance to near vision. HCPs confirmed the relevance of 
the concepts being measured for presbyopia and recommended the addition of an item assessing contrast sensitivity.
Conclusions: Developed in accordance with the FDA PRO Guidance, the findings support content validity of the 
NAVQ‑P as a suitable, well‑understood instrument of relevant near vision functioning concepts in individuals with 
phakic presbyopia. The NVCI and additional PRO instruments are appropriate to assess near vision correction inde‑
pendence, correction preference, and vision satisfaction. Future work will assess the psychometric properties of the 
NAVQ‑P and additional PRO instruments.
Keywords: Presbyopia, Content validity, Patient‑reported outcome, Cognitive debriefing, Qualitative, Interviews, 
NAVQ‑P
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The aim of the study was to evaluate the content valid-
ity of the NAVQ-P, NVCI and the additional instruments 
(NVCI, NVCP, NVS, PGIS-Presbyopia and PGIC-Presby-
opia) in individuals with phakic presbyopia through the 
conduct of qualitative research, with the ultimate objec-
tive to develop PRO instruments suitable for use as clini-
cal trial endpoints in phakic presbyopia.
Methods
Study design
This was a non-interventional, qualitative study involv-
ing participants with phakic presbyopia and health-
care professionals (HCPs). In-depth, face-to-face, 
semi-structured interviews were conducted with thirty-
five individuals with phakic presbyopia to assess the con-
tent validity of the PRO instruments. Seven additional 
interviews were conducted with HCPs to obtain a clinical 
perspective on the relevance of the items included within 
the PRO instruments.
There were five stages to the research as outlined in 
Fig.  1. A purposive sampling approach involved enrol-
ment of individuals with phakic presbyopia in the US 
(n = 15), France (n = 10) and Germany (n = 10), and 
HCP representation from the US (n = 3), France (n = 2), 
Japan (n = 1), and Germany (n = 1). These countries 
were selected to provide a representation from the US 
and Europe, and a HCP from Japan was interviewed to 
explore if there were any apparent differences in Asia. 
Both samples participated in combined concept elici-
tation (CE) and CD interviews. Findings from the CE 
section of the interviews (stage 2) have been published 
separately and are therefore not described in this article 
[23].
CD interviews were conducted across two rounds with 
individuals with phakic presbyopia (round 1/stage 3: 
n = 17; round 2/stage 5: n = 18) and HCPs (round 1/stage 
1: n = 3; round 2/stage 5: n = 4). Conducting the inter-
views in rounds enabled iterative modifications to the 
NAVQ-P, NVCI and additional instruments to be tested 
in a subsequent round of interviews (Fig. 1). Expert clini-
cal input to study design, findings and instrument modi-
fication was provided by the developer of the original 
NAVQ [18]. Ethical approval was obtained in accordance 
with requirements per study country (Additional file 1).
Study sample
Partner recruitment agencies worked with ophthalmolo-
gists/optometrists to recruit individuals with phakic 
presbyopia who met the inclusion and exclusion criteria 
(Additional file  1). Referring ophthalmologists/optome-
trists confirmed the participant’s eligibility by completing 
a Case Report Form (CRF) and ensured written informed 
consent was obtained using an Information and Consent 
Form (ICF) prior to any other study activities and prior 
Fig. 1 Study methodology. *CE concept elicitation, CD cognitive debriefing, HCP healthcare professional, FDA US Food and Drug Administration, 
PRO patient‑reported outcome, NAVQ-P Near Activity Visual Questionnaire for Presbyopia, NVCI Near Vision Correction Independence, NVCP Near 
Vision Correction Preference, NVS Near Vision Satisfaction, PGIS Patient Global Impression of Severity, PGIC Patient Global Impression of Change
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to any personal data being shared (Additional file 1). The 
recruitment agencies collected demographic informa-
tion using the demographic form and participants were 
remunerated for taking part. HCPs (N = 7) were identi-
fied based on their area of expertise and contribution to 
the field. HCPs (ophthalmologists or optometrists) were 
recruited from the US, Germany, France, and Japan.
Cognitive debriefing interview procedure
The aim of the CD interviews with individuals with pha-
kic presbyopia was to assess relevance and understanding 
of item wording, instructions, recall period and response 
options of the PRO instruments and the usability of the 
electronic PRO (ePRO) tablet device (Samsung Gal-
axy Tab E). Given seeing small text on a digital screen 
was identified in the previous literature as an impact of 
presbyopia, the ePRO was developed with this in mind 
(Roboto font size 23) and participants were asked spe-
cifically about whether they found the font size easy to 
read. Interview administration was not considered given 
the design of the ePRO was developed to be easy for indi-
viduals with phakic presbyopia to read.
The interviews were conducted by trained, experienced 
interviewers using a semi-structured interview guide 
(Additional files 2 and 3). Minor updates were made to 
the interview guide between rounds of interviews to 
correspond with modifications made to the PRO instru-
ments. Additional probes were also added to the inter-
view guide following round 1 (stage 3) interviews to 
explore any differences between participants who had 
comorbid myopia and those who did not. Figure  1 out-
lines the instrument version debriefed at each stage of the 
study. The study team sought feedback from the US Food 
and Drug Administration (FDA) between round 1 and 
round 2 interviews (stage 4).
A ‘think-aloud’ process was employed which involved 
participants being asked to speak their thoughts aloud as 
they read all instructions and completed each item on the 
ePRO device [21]. Specifically, interviews with individu-
als with phakic presbyopia utilised ‘think aloud’ discus-
sion to elicit in-depth evidence on the understanding, 
relevance and interpretation of the PRO instruments. 
Targeted probing was used to ensure elicitation of feed-
back on item relevance and whether any important con-
cepts were missing. The interview process was designed 
in line with best practice and regulatory standards in the 
assessment of content validity (FDA Guidance, Interna-
tional Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Good Research Practice [21, 24–26]). 
All interviews with individuals with phakic presbyopia 
were conducted in the participant’s local language and 
lasted approximately 60 min (approximately 45 min was 
spent on the CD part of the interview).
HCPs were asked to provide feedback on the item 
wording, whether they perceived the concept to be rel-
evant to phakic presbyopia, missing concepts, and any 
comments on the response options or recall period. All 
HCP interviews were conducted by telephone in English 
and lasted approximately 60 min (approximately 30 min 
was spent on the CD part of the interview).
Data analysis
Planned analyses and subgroup analyses was detailed 
in a qualitative analysis plan (QAP) prior to data collec-
tion. Verbatim transcripts were qualitatively analyzed 
using thematic analysis methods and ATLAS.ti software 
[27, 28]. Verbatim patient quotes were highlighted and 
grouped by theme/topic. Frequency counts were gener-
ated per item and instruction of the NAVQ-P, NVCI and 
additional PRO instruments to indicate understanding 
and relevance (yes/no/unclear), along with the genera-
tion of a list of participant verbatim statements for each 
coding domain [29]. Subgroup comparisons identified 
patterns in instrument interpretation between individu-
als with phakic presbyopia according to presbyopia sever-
ity (mild vs. moderate/severe), age of participant, country 
(US vs. France vs. Germany), and presence of co-morbid 




HCPs (N = 7)
HCPs were interviewed in the US (n = 3/7, 42.9%), France 
(n = 2/7, 28.6%), Japan (n = 1/7, 14.3%) and Germany 
(n = 1/7, 14.3%). HCPs were practicing ophthalmolo-
gists (n = 5/7, 71.4%) or optometrists (n = 2/7, 28.6%). 
All HCPs had spent over 10 years managing individuals 
with presbyopia and self-reported treating an average 
of > 31 individuals with presbyopia every month (n = 5/7, 
71.4%) or 21–30 individuals per month (n = 2/7, 28.6%). 
HCPs reported that their routine appointments with 
individuals with presbyopia were typically approximately 
once per year (n = 3/7, 42.9%), twice per year (n = 2/7, 
28.6%) or monthly (n = 2/7, 28.6%). Four HCPs (n = 4/7, 
57.1%) reported that they experienced presbyopia them-
selves, two HCPs (n = 2/7, 28.6%) reported that they did 
not, and one HCP (n = 1/7, 14.3%) did not comment on 
whether they experienced presbyopia themselves or 
not. Table 1 provides an overview of HCP demographic 
characteristics.
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Individuals with phakic presbyopia (N = 35)
The thirty-five individuals with phakic presbyopia inter-
viewed were based across the US (n = 15), France (n = 10) 
and Germany (n = 10). The mean age of the sample was 
53.5  years old (range: 40–65). There were more females 
(n = 21/35, 60.0%) than males (n = 14/35, 40.0%) inter-
viewed. A similar number of Caucasian (n = 11/35, 
36.7%) and Black/African American (n = 9/35, 30.0%) 
participants were interviewed. Data on race or ethnicity 
was not obtained for the French participants (n = 10/35, 
28.6%) in line with French legislation.
There were a higher percentage of participants who had 
‘moderate-severe’ phakic presbyopia (n = 21/35, 60.0%) 
compared with ‘mild’ phakic presbyopia (n = 14/35, 
40.0%); based on their near addition (ADD) results pro-
vided by the referring physician. Most participants 
(n = 22/35, 62.9%) were using glasses for near vision 
correction except for six participants who used con-
tact lenses (n = 6/35, 17.1%). Data on current correction 
method was missing for eight participants (n = 8/35, 
22.9%). Table  2 provides an overview of participant 
demographic and clinical characteristics.
Table 1 Healthcare professional demographic information
*Multiple answers possible
Description Total (N = 7)
Age
 Average (range) 52.1 (41–69)
Gender, n (%)
 Male 6 (85.7)
 Female 1 (14.3)
Role, n (%)
 Ophthalmologist 5 (71.4)
 Optometrist 2 (28.6)
Years in current position, n (%)
 Less than 1 year 1 (14.3)
 1–5 years 1 (14.3)
 5–10 years 1 (14.3)
 Longer than 10 years 4 (57.1)
Time spent managing individuals with presbyopia, n (%)
 10 + years 7 (100)
Average number of individuals with presbyopia seen each month, n (%)
  > 31 individuals 5 (71.4)
 21–30 individuals 2 (28.6)
Would you typically diagnose individuals with presbyopia? n (%)
 Yes 7 (100)
 No 0
If yes which methods do you use? n (%)*
 Refraction 7 (100)
 Visual acuity 6 (85.7)
 Slit lamp 2 (28.6)
 Examination of retina 2 (28.6)
How often do you see individuals with presbyopia for routine appointments? n (%)
 Once per year 3 (42.9)
 Twice per year 2 (28.6)
 Monthly 2 (28.6)
Do you experience presbyopia yourself? n (%)
 Yes 4 (57.1)
 No 2 (28.6)
 Missing data 1 (14.3)
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Table 2 Demographic and clinical characteristics of individuals with phakic presbyopia
Description France (N = 10) Germany (N = 10) USA (N = 15) Total (N = 35)
Participant demographic characteristics
Age
 Average (range) 55.9 (41–65) 51.1 (40–63) 53.6 (41–65) 53.5 (40–65)
Sex, n (%)
 Male 2 (20.0) 5 (50.0) 7 (46.7) 14 (40.0)
 Female 8 (80.0) 5 (50.0) 8 (53.3) 21 (60.0)
Race, n (%)
 Caucasian Not appropriate to collect 
in France
7 (70.0) 4 (26.7) 11 (36.7)
 Black/African American 1 (10.0) 8 (53.3) 9 (30.0)
 Asian 2 (20.0) – 2 (6.7)
 Other—Hispanic – 3 (20.0) 3 (8.6)
 Missing data 10 (100) – – 10 (28.6)
Participant self‑reported severity of presbyopia, n (%)
 Very severe 1 (10.0) 1 (10.0) 1 (6.7) 3 (8.6)
 Severe 1 (10.0) 3 (30.0) 4 (26.7) 8 (22.9)
 Moderate 7 (70.0) – 7 (46.7) 14 (40.0)
 Mild 1 (10.0) 6 (60.0) 3 (20.0) 10 (28.6)
Participant self‑reported myopia*
 No 5 (50.0) 6 (60.0) 8 (53.3) 19 (54.3)
 Yes 5 (50.0) 4 (40.0) 7 (46.7) 16 (45.7)
Participant clinical characteristics (reported by recruiting clinician)
Number of years since diagnosis*
 Average (range) 10.4 (0.5–20.9) 7.3 (1–17.1) 9.9 (0.2–34.6) 9.3 (0.2–34.6)
Visual acuity score, average (range)a
 Left eye (decimal) 0.92 (0.6–1.0) 0.67 (0.5–0.8) 0.55 (0.4–0.7) 0.68 (0.4–1.0)
 Right eye (decimal) 0.92 (0.6–1.0) 0.64 (0.4–0.8) 0.55 (0.3–1.0) 0.68 (0.3–1.0)
Severity of participants’ binocular DCNVA at 40 cm, n (%)
 Mild 2 (20.0) 6 (60.0) 5 (33.3) 13 (37.1)
 Moderate‑severe 3 (30.0) 4 (40.0) 10 (66.7) 17 (48.6)
 Information not available 5 (50.0) – – 5 (14.3)
Severity of participants’ near ADD, n (%)
 Mild 3 (30.0) 6 (60.0) 5 (33.3) 14 (40.0)
 Moderate‑severe 7 (70.0) 4 (40.0) 10 (66.7) 21 (60.0)
Clinician reported myopia/ near sightedness †
 None 6 (60.0) 5 (50.0) 8 (53.3) 19 (54.3)
 Mild 2 (20.0) – 2 (13.3) 4 (11.4)
 Moderate 1 (10.0) – 2 (13.3) 3 (8.6)
 High 1 (10.0) – 3 (20.0) 4 (11.4)
 Missing data – 5 (50.0) – 5 (14.3)
Concomitant conditions, n (%)^
 Yes: 1 (10.0) – 2 (13.3) 3 (8.6)
  Posterior detachment of the left vitreous 1 (10.0) – – 1 (2.9)
  Asthma – – 1 (6.7) 1 (2.9)
  Glaucoma – – 1 (6.7) 1 (2.9)
  Chronic obstructive pulmonary disease – – 1 (6.7) 1 (2.9)
Current treatment for presbyopia, n (%)^
 Glasses 7 (70.0) 5 (50.0) 10 (66.7) 22 (62.9)
  Unspecified 1/7 (14.3) 5/5 (100) 8/10 (80.0) 14 (40.0)
  Single vision 2/7 (28.6) – 2/10 (20.0) 4 (11.4)
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Stage 1: HCP interviews (round 1, n = 3) CD findings
Three HCPs (US n = 2, Germany n = 1) were debriefed 
the NAVQ-P v1.0 and NVS v1.0 (at this point the sat-
isfaction question formed part of the NAVQ). These 
HCPs indicated that the NAVQ-P assessed concepts 
relevant to individuals with phakic presbyopia. Two 
HCPs (n = 2/3, 66.7%) noted that the instructions in the 
NAVQ-P v1.0 may cause individuals who have co-mor-
bid myopia to answer incorrectly, given that they take 
their glasses off to be able to see up close. As a result, 
the instructions were updated from ‘… when you were 
not wearing glasses/contact lenses’, to ‘… when you 
were not wearing glasses/contact lenses to see things 
close to you (less than an arm’s length away)’.
“But people that are nearsighted who don’t have 
anything on, no glasses, no contact lenses, nothing, 
if they’re nearsighted to the proper degree, they will 
never have any symptomatic presbyopia as long as 
their glasses and their contact lenses are not used.” 
(HCP 2)
Minor changes were recommended to two items to 
ensure that the visual task examples provided in items 
were of equivalent difficulty. This included removal 
of the example ‘items on a menu’ from item 1 (which 
assessed reading small print) since this task may not 
be equivalent to other provided examples (e.g. news-
paper), given the potential for dimmed lighting in res-
taurant settings. The example of ‘gardening’ was also 
removed from item 9 (which assessed seeing objects up 
close to engage in hobbies) as the HCPs felt that gar-
dening mostly involved intermediate vision. Addition-
ally, an item to assess contrast sensitivity was added to 
the NAVQ-P v1.0 based on HCP feedback. All revisions 
were implemented ahead of the intermediary partici-
pant CE interviews (NAVQ-P v2.0).
“Not necessarily because newspaper people might 
have more light than perhaps in a dimly lit restau-
rant.” (HCP1)
“The number of tasks that you do that are actu-
ally near tasks are pretty small. I mean you’re dig-
ging a hole and you’re raking the, the ground and 
you’re, you know—gardening is not a, a near vision 
intense hobby.” (HCP2)
Stage 2: Interviews with individuals with phakic 
presbyopia (CE‑only, n = 15) CE findings
Findings from an initial round of CE interviews with a 
separate sample of 15 individuals with phakic presbyopia 
(independent of combined CE and CD rounds) contrib-
uted to the modification of the NAVQ-P v2.0 forming 
the NAVQ-P v3.0. Revisions included the addition of rel-
evant item examples, inclusion of an item to assess seeing 
objects up close in bright light, and the rewording of an 
item which assessed difficulties with contrast sensitivity 
to ensure that language was patient-friendly. The item 
which assessed satisfaction with near vision (from the 
original NAVQ) was separated from the NAVQ-P v2.0 
to form the Near Vision Satisfaction (NVS) instrument. 
Four other single-item instruments were also created: 
NVCI, NVCP, PGIS-Presbyopia, and PGIC-Presbyopia.
Stage 3: Interviews with individuals with phakic 
presbyopia (round 1, n = 17) CD findings
Item wording, response options and the recall period 
of the NAVQ-P v3.0 and additional instruments were 
generally well understood and participants appeared to 
interpret most items correctly and consistently (Fig.  2). 
Three NAVQ-P v3.0 items were misunderstood in round 
1 interviews (summarized in Table 3). These items were 
misunderstood by two or more participants including 
item 1 (which assessed seeing objects in bright light, 
understood by n = 7/17, 41.2%), items 11 (which assessed 
contrast sensitivity, understood by n = 15/17, 58.8%), and 
item 12 (which assessed maintaining focus for near vision 
activities, understood by n = 8/17, 52.9%). Overall con-
ceptual relevance of the NAVQ-P v3.0 was analyzed col-
lectively across the two rounds of CD interviews (Fig. 3).
“That needs to be changed …it says seeing objects 
close to you in bright light such as seeing dashboard 
in a car. The dashboard doesn’t have lighting that 
*One participant’s data was removed in this category only as it appeared to have an error
a Two participants data missing. ^Multiple answers possible. ~ This question was not collected on the demographic form in Germany so this information has been 
generated from what the patient reported during the interview. In addition, one patient reported myopia in the demographic form but reported that they did not 
have myopia during the interview. The clinician also reported that this patient did not have myopia, so this patient has not been counted as a myopic patient in the 
analyses of findings. †Clinicians were not asked to confirm diagnosis of myopia for the round 1 interviews
Table 2 (continued)
Description France (N = 10) Germany (N = 10) USA (N = 15) Total (N = 35)
  Multifocal 4/7 (57.1) – – 4 (11.4)
Contact lenses – 5 (50.0) 1 (6.7) 6 (17.1)
Missing data 3 (30.0) – 5 (33.3) 8 (22.9)
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bright …What you see is the light that reflects out 
there that comes.” (F55-MILD-R1-US3)
Round 1 instrument modifications
Modifications were made to the NAVQ-P v3.0 (becom-
ing NAVQ-P v4.0) based on Round 1 interview findings, 
including the addition of ‘magnifying glass’ alongside 
‘wearing glasses/contact lenses’ in the instructions and 
item stem (the first part of each question) to ensure that 
individuals would consider all possible forms of vision 
correction. The second instruction (which read ‘If you 
did not do the described activity or you have stopped for 
reasons that are not related to your vision then please 
select the ‘N/A or stopped doing this for non-visual rea-
sons’ option’) was removed as it was determined to be 
redundant. Revisions were made to the ‘not applicable’ 
response option wording to read: ‘I did not do this activ-
ity in the past seven days’. Examples within three items 
were updated, one item was reworded and two new items 
to assess ‘seeing fine detail’ and ‘difficulty adjusting from 
far vision to close vision’ were developed. Updates were 
also made to the NVCI, NVCP, NVS, PGIS-Presbyopia 
and PGIC-Presbyopia (see Table  3 for further informa-
tion about modifications made to all items). Notably, an 
alternative set of response options (‘Never’ to ‘Always’) 
was developed for the NCVI to be debriefed alongside 
the original response options (‘None of the time’ to ‘All of 
the time’) in round 2.
Stage 4: FDA feedback on NAVQ‑P v4.0 and additional 
instruments (Type‑C meeting)
Based on FDA feedback obtained, the NAVQ-P v4.0 was 
updated to form v5.0. Modifications were made to the 
instructions, item stem, and four items. One new item was 
incorporated to assess the ability to see things when glare is 
present. Findings from round 1 qualitative interviews iden-
tified that this concept was a distinct construct to difficulty 
seeing things in bright light, thus, an additional item was 
warranted. Additional wording modifications were made to 
the PGIS-Presbyopia following feedback from the FDA to 
create PGIS-Presbyopia v3.0. No further changes were made 
to the NVCI v2.0, NVCP v1.0, NVS v2.0, and the PGIC-Pres-
byopia v2.0.
Stage 5: HCP interviews (round 2, n = 4) CD findings
Four HCPs (France n = 2, US n = 1, Japan = 1) debriefed 
the instruments in round 2 (see versions in Fig. 1). These 
HCPs agreed that the NAVQ-P v5.0 and additional 
instruments would be well understood by individuals 
with phakic presbyopia and supported the clinical rel-
evance of concepts assessed. No missing concepts of 
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Fig. 2 Summary of item understanding during round 1 CD interviews
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were suggested, mainly concerning the examples pro-
vided within item wording. The changes were revisited 
following round 2 of CD interviews with individuals with 
phakic presbyopia to ensure that revisions were in-line 
with participant feedback and understanding.
“The only part of it that might get confusing is, um, 
you’re saying, um, close to you in dim light, but 
then you use the term reading a book by lamplight. 
So what you’re inherently doing in this second por-
tion of the questions, is, um, it’s, it’s almost like the 
patient is- they’re not in dim light anymore because 
they are beside a lamplight.” (HCP4)
Stage 5: Interviews with individuals with presbyopia 
(round 2, n = 18) CD findings
Item wording, response options and recall period of the 
NAVQ-P v5.0 and additional instruments were generally 
well understood and interpreted consistently (Fig. 4).
Minor issues in understanding or consistent inter-
pretation were identified for four NAVQ-P v5.0 items 
(Table  3). Item 1 (difficulty reading small printed text 
on paper) was misinterpreted by n = 2/18 (11.1%) as 
asking about reading from a tablet or smartphone. Item 
3 (difficulty reading small digital text on a tablet device) 
was misinterpreted by n = 2/18 (11.1%) to be about 
reading from a laptop. Item 7 (difficulty seeing the key-
pad on a smartphone or tablet screen) demonstrated 
an inconsistent interpretation of ‘keypad’, with n = 6/18 
(33.3%) participants discussing keyboards or buttons 
rather than focussing on the keypad on the screen. Item 
15 (ability for the eye to adjust between different vision 
fields) was generally misunderstood by n = 3/18 (16.7%) 
and also misinterpreted by n = 2/18 (11.1%) to relate to 
a change in lighting.
“A keypad is something where you press something 
down, not a touchscreen.” (F40-MILD-R2-DE1)
Round 2 instrument modifications
Modifications to NAVQ-P v5.0 item wording and 
response options were made (forming NAVQ-P v6.0). 
See Table  3 for further information about updates to 
items. Item ordering was also adjusted: the order of 
the items assessing ‘vision when glare is present’ and 
‘vision in bright light’ was reversed to avoid respond-
ents thinking about glare when responding to the bright 
light item. The alternative set of response options were 
retained for the NVCI (v3.0). No changes were made 
to the NVCP v2.0, NVS 3.0, PGIS-Presbyopia v3.0 and 
PGIC-Presbyopia v2.0.
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Fig. 3 Summary of overall conceptual relevance (round 1 and round 2 combined)
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Item relevance assessed across round 1 and round 2 
interviews with individuals with phakic presbyopia (n = 35)
Given the concepts assessed did not change across both 
rounds (apart from some new items being added), relevance 
is summarised collectively for both round 1 (stage 3) and 
round 2 (stage 5) interviews with individuals with phakic 
presbyopia. All concepts of the NAVQ-P were considered 
relevant to at least 30% of individuals with phakic presbyo-
pia (Fig. 3). Twelve of the fifteen (n = 12/15, 80.0%) item con-
cepts in the NAVQ-P were considered relevant to at least 
50% of participants. The NVCI instrument was relevant to a 
total of 26 participants (n = 26/35, 74.3%). Assessment of rel-
evance was not applicable to the NVCP, NVS, PGIS-Presby-
opia and PGIC-Presbyopia instruments.
“Reading small printed text on paper such as news-
paper—um, oh extremely difficult as I said before. 
Everything has to be large print.” (M50-MOD-
R2-US8)
The concepts listed below demonstrated lower rel-
evance (relative to other items) for participants with 
phakic presbyopia. Participants either did not report 
difficulty with the described visual activity in relation to 
their presbyopia or did not perform the task in the past 
seven days (Fig.  3). These items were retained, pending 
psychometric evaluation, but were flagged as potential 
candidates for deletion at a later stage.
• Reading on a tablet device: n = 15/35 (42.9%) partici-
pants reported as relevant.
• Seeing things in bright light: n = 11/35 (31.4%) par-
ticipants reported as relevant.
• Ability for the eye to adjust between different vision 
fields: n = 8/18 (44.4%) participants reported as rel-
evant.
“I don’t have difficulties to adjust. Because in any 
way, I’m blurry from a distance, I’m blurry at close 
distance so...” (F58-MOD-R2-FR2)
General feedback on the instruments from round 1 
and round 2 interviews with individuals with phakic 
presbyopia (n = 35)
No important concepts were identified as missing by 
participants. Participants were asked about the usability 
of the ePRO, with most participants (n = 11/15, 73.3%) 
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Fig. 4 Summary of item understanding during round 2 CD interviews
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text size was adequate, and n = 15/17 (88.2%) report-
ing no concerns with navigation on the device. A small 
number of participants (n = 3/35, 8.6%) estimated how 
long it would take them to complete the instruments, 
which ranged from 10 (n = 2/3, 66.7%) to 20 min (n = 1/3, 
33.3%). However, these estimations may be inflated given 
that the instruments were completed during the inter-
view which involved discussing the response to each item 
following completion.
“I think I would have needed 10  min.” (F44-MILD-
R2-DE3)
Discussion
To address the need for a PRO that assesses phakic 
presbyopia near vision functioning, the present study 
details the modification and content validity testing of 
the NAVQ-P and additional instruments (NVS, NVCI, 
NVCP, PGIS-Presbyopia and PGIC-Presbyopia). Findings 
suggest that the NAVQ-P demonstrates content valid-
ity as an assessment of near vision functioning which 
reflects the most important concerns of individuals with 
phakic presbyopia. The additional instruments are appro-
priate to assess near vision correction independence 
(NVCI), near vision correction preference (NVCP), and 
near vision satisfaction (NVS). The study involved the 
successful modification of the original NAVQ to address 
the limitations of the use of this instrument in clinical 
studies with individuals with phakic presbyopia.
The study had been designed in line with best practice 
and standards outlined in regulatory guidance on the 
steps necessary to establish content validity and feedback 
from the FDA was obtained [21, 24, 25, 30]. As a result, 
the NAVQ-P is a product of rigorous research involv-
ing an initial literature and instrument review and social 
media listening, multiple rounds of combined qualitative 
CE and CD interviews (with individuals with phakic pres-
byopia and HCPs) and engagement with regulators. Find-
ings from an initial literature and social media review 
informed revision of the original NAVQ [16, 22]. The 
NAVQ-P was then subject to CD with individuals with 
phakic presbyopia and mapped alongside findings from 
qualitative CE interviews (described elsewhere) [23] to 
ensure all important concepts were included. The con-
cepts included in the NAVQ-P also reflect findings from 
previous literature investigating the individual experience 
of presbyopia [8, 10–12, 14, 31]. The two rounds of CD 
interviews allowed for modifications to be implemented 
to the instrument following round 1 interviews, which 
could then be evaluated during round 2 interviews.
Participants demonstrated good understanding of 
the NAVQ-P item wording, recall period and response 
options in round 2 (stage 5) interviews. The three new 
items that were added following round 1 CD interviews 
and FDA feedback were well understood and had rea-
sonably high relevance to presbyopic participants; sup-
porting inclusion in the NAVQ-P. A small number of 
modifications were made following round 2 based on the 
CD findings to enhance interpretation. Additionally, for-
matting changes were made to enhance comprehension. 
HCPs confirmed that the NAVQ-P concepts were clini-
cally relevant to individuals with phakic presbyopia.
As the NAVQ-P and additional instruments were 
developed and cognitively debriefed in an electronic 
mode of administration (on a tablet device), the inter-
views confirmed usability of the ePRO and that the font 
size of an electronic administration of instruments was 
appropriate for individuals with phakic presbyopia. In 
addition, throughout the development of the NAVQ-
P it became apparent that individuals who experienced 
both myopia and presbyopia used their glasses differ-
ently to see up close. Those with comorbid myopia took 
their long-distance glasses off to see up close, while those 
with phakic presbyopia only put their reading glasses on 
to see up close. With this in mind, the instructions were 
updated to specifically ask participants to think about 
when they are not wearing their glasses to see things 
close to them. As a result, the instrument is suitable for 
use in individuals with phakic presbyopia who do or do 
not have comorbid myopia.
A key strength of this study was that clinical relevance 
and development of the instruments was ensured via 
collaboration with the NAVQ developer and specialist 
HCPs. Regulatory advice guided further development 
of the NAVQ-P and NVCI instruments and was pivotal 
in ensuring that the NAVQ-P and NVCI meet the qual-
ity standards for content validity, supporting use of these 
instruments as clinical trial endpoints with potential to 
support label claims. The NAVQ-P provides a unique 
opportunity to assess near vision functioning that is spe-
cific to individuals with phakic presbyopia. Other PROs 
commonly used in ophthalmology populations to assess 
visual function (such as the NEI RQL-42 or the NEI 
VFQ-25) assess some concepts that are not relevant to 
presbyopia, such as ability to do distance vision activities 
or limitations with peripheral vision, have been devel-
oped with individuals who have received refractive eye 
surgery, or require individuals to respond to items think-
ing about their vision when using vision correction [19, 
20].
The study sample included individuals with phakic 
presbyopia from multiple countries (US, Germany, and 
France) and quotas were used to ensure the sample had 
diverse demographic and clinical characteristics. This 
enables confidence that findings are representative of 
the wider phakic presbyopia population and provides 
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evidence of cross-cultural validity, specifically in the 
US and Europe. Additionally, the HCPs from the US, 
France, Japan and Germany all confirmed clinical rel-
evance of the NAVQ-P and additional instruments 
in these countries, further supporting cross-cultural 
validity and clinical relevance. A wide range of refrac-
tive error was included in the sample, with this study 
confirming the suitability of the use of the NAVQ-P and 
additional instruments in individuals with phakic pres-
byopia, regardless of their refractive error (i.e. severity).
While multiple countries were included, all were 
western countries in highly developed nations, there-
fore, further research in countries in Asia, South Amer-
ica and/or Africa in the future would be of interest to 
provide further insight regarding the degree to which 
the findings can be generalized cross-culturally.
Conclusions
The study findings reported here support the content 
validity of the newly adapted NAVQ-P, NVCI, NVCP, 
NVS, PGIS-Presbyopia and PGIC-Presbyopia in indi-
viduals with phakic presbyopia. Psychometric evalua-
tion is planned to support finalization of scoring (with 
possible item reduction), and assess the validity, reli-
ability, and importantly ability to detect change over 
time for the instruments, ultimately confirming the 
adequacy of the NAVQ-P and additional instruments as 
clinical trial endpoints in support of potential labelling 
claims.
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